Bisphosphonates: new therapeutic agents for the treatment of bone tumors.
about
Bone Tumor Environment as a Potential Therapeutic Target in Ewing SarcomaAnti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidencesKey roles of the OPG-RANK-RANKL system in bone oncologyReactive oxygen species and autophagy associated apoptosis and limitation of clonogenic survival induced by zoledronic acid in salivary adenoid cystic carcinoma cell line SACC-83Experiments and synthesis of bone-targeting epirubicin with the water-soluble macromolecular drug delivery systems of oxidized-dextran.Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcomaA combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis.Zoledronic acid sensitizes renal cell carcinoma cells to radiation by downregulating STAT1Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration.Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cellsTumour macrophages as potential targets of bisphosphonates.Involvement of MET/TWIST/APC combination or the potential role of ossification factors in pediatric high-grade osteosarcoma oncogenesisLiposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma.Skeletal complications of breast cancer therapiesRecent advances in the management of osteosarcoma and forthcoming therapeutic strategies.Potential use of bisphosphonates in invasive extramammary Paget's disease: an immunohistochemical Investigation.L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer.Nanostructured hyaluronic acid-based materials for active delivery to cancer.Reduced-intensity conditioning in allogeneic stem cell transplantation for hematological malignancies: a historical perspective.Drugs targeting the bone microenvironment: new therapeutic tools in Ewing's sarcoma?Current therapeutic strategies and novel approaches in osteosarcoma.The critical role of bisphosphonates to target bone cancer metastasis: an overview.Drugs in early clinical development for the treatment of osteosarcoma.Well-differentiated hand liposarcoma with bone metastases treated successfully with zoledronic Acid.Intravenous bisphosphonate-associated osteonecrosis of the jaw.Significance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancer.Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process.The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts.Immunomodulatory effect of bisphosphonate risedronate sodium on CD163+ arginase 1+ M2 macrophages: the development of a possible supportive therapy for angiosarcoma.Hydro-nium (3-oxo-1-phosphono-1,3-dihydro-isobenzofuran-1-yl)phospho-nate.Molecular alterations associated with osteosarcoma development.The Bone Niche of Chondrosarcoma: A Sanctuary for Drug Resistance, Tumour Growth and also a Source of New Therapeutic Targets.Bone-targeted methotrexate-alendronate conjugate inhibits osteoclastogenesis in vitro and prevents bone loss and inflammation of collagen-induced arthritis in vivo.In vivo distribution of zoledronic acid in a bisphosphonate-metal complex-based nanoparticle formulation synthesized by a reverse microemulsion method.Novel RANK antagonists for the treatment of bone-resorptive disease: theoretical predictions and experimental validation.Effect of β-tricalcium phosphate coated with zoledronic acid on human osteoblasts and human osteoclasts in vitro.Zoledronate Triggers Vδ2 T Cells to Destroy and Kill Spheroids of Colon Carcinoma: Quantitative Image Analysis of Three-Dimensional Cultures.
P2860
Q26771376-57EF1CF4-D1F2-45FF-9F2D-34B889DA11E3Q26863493-40BC223A-F790-49E3-B279-E58766558424Q28287394-F7EED20B-AB14-4D6B-9D1E-06C35171AA2FQ28540022-0AF3C319-9384-49CA-AB7C-B6D446EF99EFQ30729687-05881DAF-FF69-45A4-8856-5B958D30095EQ34365891-4C3D0A46-5D33-46B4-8180-68C9E501D8E1Q34413330-1A677DC2-B168-4158-80A1-2D9DF53BB3E0Q34760588-E4200865-694A-469D-AC09-B8665FFABE15Q35115510-7CC7F476-4881-4089-99AB-3624AEDCAE96Q35458425-26F7BA5F-BBC8-4853-8EC7-1709247DB21EQ35547309-5E50D0D3-3665-4D94-97BC-1D780AB867D5Q35945084-D3446801-E0E3-4056-9116-5315D2EAAA51Q36512499-5587E5DD-B9FF-48F2-B420-E7F3FF21B111Q36633831-B3BA219A-BE49-4DD4-9CCF-65E9CCF0AE3DQ36731426-1B240759-062A-458C-8E06-7B4C250E37BCQ36765862-85564DC2-77F3-4FA2-8D0B-C158D13E238AQ36853886-F5422C3C-E0F6-424B-9416-0F97AF44B85FQ37724371-C18996AE-EBCA-4F9F-89A7-8BDC769E96E9Q37966693-B33BA920-8AEA-48D3-9127-737F7325179EQ38129954-C4D04B38-DA93-434F-9401-E57FD8FD950EQ38161735-1ED11B20-ABC4-43FC-8CA5-5D5781C19D70Q38247428-822608B3-18FA-44B7-BC9F-41F747F7380CQ38955517-FD7CB778-5884-4074-A9B6-F8273D5CB801Q39254815-E4ADDC0B-859B-44C1-AEF3-9370D01493CCQ39328331-B13FE364-CF9C-4967-8A96-2197481E6835Q39466674-F3D4666B-707E-408D-899D-46C5B1D64CF6Q39640530-BF646286-1810-4907-9843-DA13CBEEFBF7Q39851518-B90C778A-D412-41C3-B1F0-031550B9A762Q41875277-E9D4126B-B21F-4013-AD63-9AFEFFF26C37Q41908059-0C3AFE0D-6D7E-4BFC-9D06-8606C7DB9A19Q42070262-B4B73200-0E1E-455E-A8AF-131CE7123D74Q42084526-8F870348-8A27-41C4-844E-04ED45F97379Q47199326-630DCA43-FB09-493C-BA38-97F67F1F88EAQ50691033-EC5AC1D6-2057-4674-8CA4-A2C0CD68EDECQ51760981-54504E75-FBD8-4FCC-94F8-BD2F3E9EF45FQ52893349-1BD3ED82-0196-4128-A999-D7D12A9CD0DBQ55310862-57D7B38E-1BBB-4458-9AD3-91781768F058
P2860
Bisphosphonates: new therapeutic agents for the treatment of bone tumors.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Bisphosphonates: new therapeutic agents for the treatment of bone tumors.
@ast
Bisphosphonates: new therapeutic agents for the treatment of bone tumors.
@en
type
label
Bisphosphonates: new therapeutic agents for the treatment of bone tumors.
@ast
Bisphosphonates: new therapeutic agents for the treatment of bone tumors.
@en
prefLabel
Bisphosphonates: new therapeutic agents for the treatment of bone tumors.
@ast
Bisphosphonates: new therapeutic agents for the treatment of bone tumors.
@en
P2093
P1476
Bisphosphonates: new therapeutic agents for the treatment of bone tumors.
@en
P2093
Benjamin Ory
François Gouin
Françoise Rédini
Jonathan R Green
P304
P356
10.1016/J.MOLMED.2004.05.007
P577
2004-07-01T00:00:00Z